CJC-1295 (No DAC) + Ipamorelin 5/5 mg

CJC-1295 (No DAC) + Ipamorelin for research: identity and specifications

CJC-1295 (No DAC) + Ipamorelin is a blend of two synthetic peptides in a single vial: CJC-1295 without DAC (modified GRF 1-29), a short-half-life 29-amino-acid analog of growth hormone-releasing hormone (GHRH; CAS 863288-34-0 / 446036-97-1), and ipamorelin, a pentapeptide ghrelin-receptor agonist (CAS 170851-70-4). Supplied as a 10 mg total vial (5 mg + 5 mg), lyophilized powder, with no fillers, carriers or excipients, at ≥98% purity by HPLC and the lot-specific value reported on the certificate of analysis.

Scientific background

The two components act on different receptors of the somatotropic axis: the GHRH analog on the GHRH receptor of pituitary somatotroph cells, and ipamorelin, a selective agonist, on the growth hormone secretagogue receptor (GHS-R1a). In experimental models, the combination is examined for interaction between the two signaling pathways and for pulsatile growth hormone release in pituitary cell culture.

Preclinical literature studies each component alone and in combination, in cell-based assays and rodent models of the axis, always under controlled bench conditions and without extrapolating results to human or veterinary use.

• GHRH receptor and GHS-R1a signaling in pituitary cell models
• Interaction between two secretagogue pathways
• Pulsatile growth hormone release in experimental systems
• Selectivity comparisons among secretagogue peptides

Technical specifications

Analytical quality and chain of custody

Every lot of CJC-1295 (No DAC) + Ipamorelin is synthesized in registered facilities, with independent analytical verification by third-party laboratories and full chain-of-custody documentation. The certificate of analysis (COA) for each lot can be reviewed before purchase, recording HPLC purity and the other quality-control parameters used to release the material.

Reconstitution and laboratory handling

As a bench procedure, the lyophilized vial is reconstituted with a known volume of a suitable solvent, added along the inner wall of the vial, followed by gentle swirling until fully dissolved, without vigorous shaking. The reconstituted solution should be kept refrigerated and protected from light, and used in controlled assays within the stability period validated by the laboratory. Handling must be performed only by qualified personnel, in a bench environment suitable for in vitro experimentation, with lot number and storage conditions documented according to good laboratory practice.

Frequently asked questions

What is the purity of the CJC-1295 (No DAC) + Ipamorelin supplied?

≥98% by HPLC, with the lot-specific value reported on the certificate of analysis (COA).

What are the components of the blend?

CJC-1295 without DAC (PubChem CID 56841945) and ipamorelin (PubChem CID 9831659), at 5 mg + 5 mg in a single vial.

How should the blend be stored?

At -20 °C, protected from light and moisture, as a lyophilized powder until reconstitution.

Does the certificate of analysis come with the lot?

Yes, every lot has a matching COA that can be verified before purchase using the button on this page.

Who can purchase CJC-1295 (No DAC) + Ipamorelin?

Sales are restricted to qualified researchers and institutions, for laboratory use only, as detailed in the research-use-only notice on this page.

See the peptide reference guide, the page on how every lot is tested by HPLC and COA. Molecular structures in PubChem: CJC-1295 (No DAC) and Ipamorelin.

Research use only (RUO). This material is supplied for in vitro laboratory research only. It is not a drug, dietary supplement or cosmetic, and it is not intended for human or veterinary use, or for the diagnosis or treatment of any condition. Sales are restricted to researchers and institutions.